ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), announced today that positive results from the Phase 2 CLARITY study evaluating pimavanserin as adjunctive treatment in patients with major depressive disorder (MDD) have been published online by The Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology (ASCP). In this 10-week, randomized, double-blind, placebo-controlled study (n=207), pimavanserin met the overall prima